APX001
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia, Invasive Candidiases, Candida Infection
Trial Timeline
Dec 13, 2019 → Dec 31, 2020
NCT ID
NCT04148287About APX001
APX001 is a phase 2 stage product being developed by Basilea Pharmaceutica for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04148287. Target conditions include Candidemia, Invasive Candidiases, Candida Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04148287 | Phase 2 | Completed |
| NCT03604705 | Phase 2 | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 85 |
| Micafungin | Astellas Pharma | Approved | 85 |
| AmBisome | Gilead Sciences | Approved | 84 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 76 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 84 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 76 |
| Anidulafungin | Pfizer | Phase 3 | 76 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 72 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 47 |